{
    "organizations": [],
    "uuid": "6355e7d9e9f9ce30fd8ff688844ae4e7e24edde5",
    "author": "",
    "url": "https://www.reuters.com/article/brief-azurrx-biopharma-announces-propose/brief-azurrx-biopharma-announces-proposed-public-offering-of-common-stock-idUSASC09YBT",
    "ord_in_thread": 0,
    "title": "BRIEF-Azurrx Biopharma Announces Proposed Public Offering Of Common Stock",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 30 (Reuters) - AzurRx BioPharma Inc:\n* AZURRX BIOPHARMA ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK\n* AZURRX BIOPHARMA INC - INTENDS TO USE PROCEEDS FROM OFFERING FOR EXPENSES ASSOCIATED WITH AZURRXâ€™S CONTINUING CLINICAL DEVELOPMENT & TESTING OF MS1819 Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-30T23:36:00.000+03:00",
    "crawled": "2018-05-01T00:00:30.016+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "azurrx",
        "biopharma",
        "inc",
        "azurrx",
        "biopharma",
        "announces",
        "proposed",
        "public",
        "offering",
        "common",
        "stock",
        "azurrx",
        "biopharma",
        "inc",
        "intends",
        "use",
        "proceeds",
        "offering",
        "expense",
        "associated",
        "azurrx",
        "continuing",
        "clinical",
        "development",
        "testing",
        "ms1819",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}